Multiple respiratory virus threats in winter
Measures to reduce transmission of SARS-CoV-2 have also been effective in reducing the transmission of other endemic respiratory viruses. As many countries decrease the use of such measures, SARS-CoV-2 will circulate with other respiratory viruses, increasing the probability of co-infections.
Experts predict that there may be a triple virus epidemic this winter due to the combination of seasonal peaks of influenza (Flu) and respiratory syndrome virus (RSV) with the SARS-CoV-2 virus epidemic. The number of cases of Flu and RSV this year is already higher than that of the same period in previous years. The new variants BA.4 and BA.5 of the SARS-CoV-2 virus have aggravated the epidemic once again.
At the "World Flu Day 2022 Symposium" on November 1, 2022, Zhong Nanshan, an academician of the Chinese Academy of Engineering, comprehensively analyzed the flu situation at home and abroad, and made the latest research and judgment on the current situation. "The world is still facing the risk of superimposed epidemics of the SARS-CoV-2 virus epidemic and the influenza epidemic.” he pointed out, “Especially this winter, it still need to strengthen research on the scientific issues of influenza prevention and control." According to the statistics of US CDC, the number of hospital visits for respiratory infections in the United States has increased significantly due to a combination of influenza and new coronary infections.
The increase in RSV detections and RSV-associated emergency department visits and hospitalizations in multiple U.S. regions, with some regions nearing seasonal peak levels. At present, the number of RSV infection cases in U.S. has reached the highest peak in 25 years, causing children's hospitals to be overwhelmed, and some schools have been closed.
The influenza epidemic broke out in Australia in April this year and lasted for nearly 4 months. As of September 25, there were 224,565 laboratory-confirmed cases of influenza, resulting in 305 related deaths. In contrast, under the SARS-CoV-2 virus epidemic prevention measures, there will be about 21,000 flu cases in Australia in 2020 and fewer than 1,000 in 2021.
The 35th weekly report of China Influenza Center in 2022 shows that the proportion of influenza cases in northern provinces has been higher than the level of the same period in 2019-2021 for 4 consecutive weeks, and the future situation will be more critical. As of mid-June, the number of influenza-like cases reported in Guangzhou has increased by 10.38 times compared with last year.
The results of an 11-country modeling study released by The Lancet Global Health in October showed that the susceptibility of current population to influenza has increased by up to 60% compared to before the epidemic. It also predicted that the peak amplitude of the 2022 flu season will increase by 1-5 times, and the epidemic size will increase by up to 1-4 times.
212,466 adults with SARS-CoV-2 infection who were admitted to hospital. Tests for respiratory viral co-infections were recorded for 6,965 patients with SARS-CoV-2. Viral co-infection was detected in 583 (8·4%) patients: 227 patients had influenza viruses, 220 patients had respiratory syncytial virus, and 136 patients had adenoviruses.
Co-infection with influenza viruses was associated with increased odds of receiving invasive mechanical ventilation compared with SARS-CoV-2 mono-infection. SARS-CoV-2 co-infections with influenza viruses and adenoviruses were each significantly associated with increased odds of death. The OR for invasive mechanical ventilation in influenza co-infection was 4.14 (95% CI 2.00-8.49, p=0.0001). The OR for in-hospital mortality in influenza co-infected patients was 2.35 (95% CI 1.07-5.12, p=0.031). The OR for in-hospital mortality in adenovirus co-infected patients was 1.6 (95% CI 1.03-2.44, p=0.033).
The results of this study clearly tell us that co-infection with the SARS-CoV-2 virus and influenza virus is a particularly dangerous situation.
Before outbreak of the SARS-CoV-2, symptoms of different respiratory viruses were very similar, but the treatment methods were different. If patients do not rely on multiple tests, the treatment of respiratory viruses will be further complicated, and it will easily waste hospital resources during high-incidence seasons. Therefore, multiple joint tests play an important role in clinical diagnosis, and doctors are able to give differential diagnosis of pathogens in patients with respiratory symptoms through a single swab sample.
Macro & Micro-Test SARS-CoV-2 Respiratory Multiple Joint Detection Solution
Macro & Micro-Test has technical platforms such as fluorescent quantitative PCR, isothermal amplification, immunization, and molecular POCT, and provides a variety of SARS-CoV-2 respiratory joint detection products. All products have obtained EU CE certification, with excellent product performance and positive user experience.
1. Real time fluorescent RT-PCR kit for detecting six kinds of respiratory pathogens
Internal Control: Fully monitor the experimental process to ensure the quality of experiments.
High Efficiency: Multiplex real-time PCR detect different target specific for SARS-CoV-2,Flu A, Flu B, Adenovirus, Mycoplasma pneumoniae, and Respiratory syncytial virus.
High sensitivity: 300 Copies/mL for SARS-CoV-2, 500Copies/mL for influenza A virus, 500Copies/mL for influenza B virus, 500Copies/mL for respiratory syncytial virus, 500Copies/mL for mycoplasma pneumoniae, and 500Copies/mL for adenovirus.
2. SARS-CoV-2/Influenza A /Influenza B Nucleic Acid Combined Detection Kit (Fluorescence PCR)
Internal Control: Fully monitor the experimental process to ensure the quality of experiments.
High Efficiency: Multiplex real-time PCR detect different target specific for SARS-CoV-2,Flu A and Flu B.
High sensitivity: 300 Copies/mL of SARS-CoV-2,500Copies/mL of lFV A and 500Copies/mL of lFV B.
3. SARS-CoV-2, Influenza A and Influenza B Antigen Detection Kit (Immunochromatography)
Easy To Use
Room Temperature Transportation & storage at 4-30°℃
High sensitivity & specificity
| Product Name | Specification |
| Real time fluorescent RT-PCR kit for detecting six kinds of respiratory pathogens | 20 tests/kit, 48 tests/kit, 50 tests/kit |
| SARS-CoV-2/Influenza A /Influenza B Nucleic Acid Combined Detection Kit (Fluorescence PCR) | 48 tests/kit, 50 tests/kit |
| SARS-CoV-2, Influenza A and Influenza B Antigen Detection Kit (Immunochromatography) | 1 test/kit, 20 tests/kit |
Post time: Dec-09-2022